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One Sentence Summary: Single-cell RNA-seq of a mouse model of multiple 24 
sclerosis uncovers new oligodendrocyte populations, putative disease markers and 25 
suggests new mechanisms underlying the pathogenesis of disease.  26 
 27 
 28 
  29 
 
2
Introductory paragraph (202 words) 30 
Multiple Sclerosis (MS) is characterised by an immune system attack targeting 31 
myelin, which is produced by oligodendrocytes (OLs). We performed single-cell 32 
transcriptomic analysis of OL lineage cells from the spinal cord of mice induced 33 
with experimental autoimmune encephalomyelitis (EAE), which mimics several 34 
aspects of MS. We found unique OLs and OL precursor cells (OPCs) in EAE 35 
and uncovered several genes specifically alternatively spliced in these cells. 36 
Surprisingly, EAE-specific OL-lineage populations expressed genes involved in 37 
antigen processing and presentation via major histocompatibility complex class I 38 
and II (MHC-I and -II), and in immunoprotection, suggesting alternative 39 
functions of these cells in a disease context. Importantly, we found that disease-40 
specific oligodendroglia are also present in human MS brains and that a 41 
substantial number of genes known to be susceptibility genes for MS, so far 42 
mainly associated with immune cells, are expressed in the OL lineage cells. 43 
Finally, we demonstrate that OPCs can phagocytose and that MHC-II expressing 44 
OPCs can activate memory and effector CD4+ T cells. Our results suggest that 45 
OLs and OPCs are not passive targets but instead active immunomodulators in 46 
MS. The disease-specific OL lineage cells, for which we identify several 47 
biomarkers, may represent novel direct targets for immunomodulatory 48 
therapeutic approaches in MS. 49 
 50 
(main text:  3055 words) 51 
The adaptive immune system is currently thought to be the most likely aetiological 52 
component for MS, although microglia have been suggested to also have a role1,2. We 53 
have shown that OLs, whose myelin is thought to be a passive target of the immune 54 
system in MS, are heterogeneous in mouse3,4. To investigate whether specific OL 55 
populations are targeted in MS, we isolated single cells from the spinal cord of control 56 
(treated with Complete Freund's Adjuvant, CFA) or EAE mice (Fig. 1a). Cells from 57 
EAE mice were collected at the peak of the disease (score=3, indicating total 58 
hindlimb paralysis, Fig. 1b) and we performed Smart-seq25 single cell RNA-seq (Fig. 59 
1a). OL-lineage cells were isolated by fluorescence activated cell sorting (FACS) 60 
GFP+ cells from EAE-induced Pdgfra-H2B-GFP transgenic mice6 (enriching for 61 
OPCs and “young” OLs, that had differentiated recently), and Pdgfra-Cre-LoxP-62 
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GFP7, (containing mainly “old” OL-lineage cells labelled with GFP since early 63 
development, but also “young” OLs and OPCs; Fig. 1a and Supplementary Fig. 1a).  64 
 65 
EAE mice spinal cord cells segregated from CFA control mice, with a subset of 66 
clusters uniquely found in EAE (Fig. 1c, Supplementary Fig. 1b,e). Clustering 67 
analysis (GeneFocus pipeline, see Methods and Supplementary Fig. 2) revealed 68 
thirteen OL lineage clusters, including four clusters of OPCs, one differentiation-69 
committed oligodendrocyte precursor (COP), one newly formed OL (NFOL) and 70 
eight mature OL (MOLs; Fig. 1d and Supplementary Fig. 1b). We also identified 71 
vascular and leptomeningeal cells (VLMCs)3,4, consistent with the labelling of this 72 
population with Pdgfra, and microglia-like cells (which, while they could also include 73 
macrophages, we refer to as microglia; Fig. 1c and Supplementary Fig. 1b), which 74 
could reflect transient Pdgfra expression in these cells, or phagocytosis of myelin-75 
associated GFP. 76 
 77 
EAE-enriched OPC populations comprised OPCcyc (cycling), OPC2 and OPC3; 78 
distinct from the OPC1 population found in healthy mice (Supplementary Fig. 1e) that 79 
shares transcriptional profile similar to previously identified postnatal and adult 80 
mouse OPCs3,4 (Fig. 1e and Supplementary Fig. 3d-f). Dimensionality reduction using 81 
non-negative matrix factorization (NNMF) yielded a rank of 8 components (see 82 
Methods). Removal of components 7 and 8 that correlated to S and G2 phase cell-83 
cycle genes revealed that OPCcyc can be further deconvoluted, suggesting that the 84 
OPCcyc population describes a mixture of cell state transitions from OPC1, OPC2 85 
and OPC3 (Supplementary Fig. 3). Comparison of OPC populations showed specific 86 
expression of genes such as Rph3a, Adora2b in OPC1, Phyhd1, Sult1a1 in OPC2 and 87 
Slc14a1 in OPC3 (Fig. 1e and Supplementary Table 1). OPC2 and OPC3 clusters 88 
displayed unique expression of Fcgr2b, Mylk, Lgals1 (Fig. 1e, g, Supplementary Fig. 89 
4a and Supplementary Table 1), when compared to OPC1, and increased levels of 90 
Myrf (Fig. 1e), a transcription factor necessary for myelination8, and decreased levels 91 
of Hes1 and Hes5 (Supplementary Fig. 4a), that keep OPCs in a progenitor state9. The 92 
COPs and NFOLs expressing Col20a1 (Fig. 1g) and Syt4 (Supplementary Fig. 4a) 93 
were mostly from EAE mice. Thus, OPCs undergo proliferation and differentiation in 94 
EAE10,11, but also transition to previously unidentified transcriptional states. 95 
 96 
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MOLs presented several markers identified in Marques et al.4, and could be 97 
subcategorized accordingly (Fig. 1d, f and Supplementary Fig. 1c). EAE-associated 98 
MOL lineage populations expressed unique genes, absent or very low expressed in 99 
healthy controls. Klk8, Itga8, Tlr3, Trim34a were enriched in MOL1/2-EAE; Plin4, 100 
Sult1a1 and Zfand4 in MOL5/6-EAE-a; and S100a10, RNAse4 and Tnfrsf1a, a MS 101 
susceptibility gene,12 in MOL5/6-EAE-b (Fig. 1f, g, Supplementary Fig. 4a and 102 
Supplementary Table 1). We found disease-specific markers in OL lineage cells such 103 
as Igtp, Nlrc5, and Serpina3n (Fig. 2b and Supplementary Fig. 4a). Il12rb1 was 104 
present in all MOL populations found in EAE mice (Fig. 1g). All OL lineage clusters 105 
comprised cells from both transgenic mouse lines, with the exception of MOL5/6-106 
EAE-a, from Pdgfra-H2B-GFP mice, which might thus be composed of “young” OLs 107 
(Supplementary Fig. 1e). 108 
 109 
To identify gene-transcription trends, we decomposed the dataset into components 110 
using NNMF (Supplementary Fig. 4b) and found 19 robust gene modules, including 111 
two that were uniquely associated with EAE: module 1, present in a subset of EAE 112 
cells comprising genes related to interferon response pathways and MHC-I and -II 113 
genes, and module 13 restricted to the MOL5/6-EAE-a population, which contained 114 
genes such as Plin4, Hif3a, and Fam107a (Supplementary Fig. 4b). Similar results 115 
were obtained when performing GO/Reactome analysis (Supplementary Fig. 4c and 116 
5a, and Supplementary Table 3). We also uncovered 360 genes that were alternatively 117 
spliced in EAE OL-lineage cells, with either exon exclusion or inclusion 118 
(Supplementary Table 2). Gene Ontology (GO)/reactome analysis showed that genes 119 
with alternatively spliced exons in EAE OPCs were related to regulation of 120 
transcriptional elongation from RNA Pol II (exon exclusion), membrane trafficking 121 
(exon inclusion), and RNA-splicing components (exon exclusion; Supplementary Fig. 122 
5b and Supplementary Table 3). We also found evidence of alternative splicing in 123 
EAE in several genes involved in myelination and MS, including the myelin genes 124 
Mbp (as previously reported13), Mobp, Pdgfa and the Ifih1 gene, in which MS-125 
associated polymorphisms have been found14 (Fig. 1.h, i Supplementary Fig. 5c and 126 
Supplementary Table 2).  127 
 128 
We performed RNAscope in situ hybridization (ISH) and immunohistochemistry 129 
(IHC) in EAE spinal cords, against several markers of the identified clusters, such as 130 
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Klk8, which specifically marks MOL1/2-EAE (Fig. 1g) and Hopx, which marks 131 
MOL24. While control spinal cords exhibited sparse Klk8 expression we observed a 132 
strong induction of Klk8 in a subset of Hopx+/Sox10+ MOL2 in EAE mice (Fig. 2a). 133 
We also confirmed the presence of PLIN4 protein (enriched in MOL5/6 EAE-a) by 134 
performing IHC on spinal cords and found elevated GFP/PLIN4 double positive cells 135 
(from the Pdgfra-H2B-GFP mouse) and Sox10/PLIN4 (Supplementary Fig. 6a) in 136 
EAE mice. Thus, Klk8 and Plin4 are new markers of subpopulations of EAE-137 
responsive MOLs. 138 
 139 
All oligodendroglia in EAE displayed elevated Serpina3n expression (Fig. 2b), 140 
encoding a serine protease inhibitor that has been shown to reduce EAE severity and 141 
induce neuroprotection15.  We confirmed the increase in Serpina3n in EAE by 142 
RNAscope ISH, especially notable within Sox10+ cells (Fig. 2c). The expression of 143 
this molecule reached such high levels in EAE, that we could no longer detect single 144 
dots. Interestingly, we found expression of additional genes of the Serpina3 family, 145 
including Serpina3h, Serpina3c, Serpina3i, Serpina3f and Serpina3g specific to 146 
MOL1/2-EAE (Fig. 2b), which could suggest that this population might be protected 147 
against direct damage by T- or NK-cells. This population also expresses the gene 148 
Serping1 (Fig. 2b) encoding for an inhibitor of complement activation, another 149 
possible mechanism of immunoprotection.  150 
 151 
MHC-I genes such as H2-K1, H2-D1, H2-T23, B2m, and genes necessary for antigen 152 
processing and binding to MHC-I molecules, such as Psmb9, Tap1 and Tap2 were 153 
significantly increased upon EAE induction in OL lineage cells (Fig. 2d and 154 
Supplementary Table 1). Thus, EAE OLs might be direct targets of cytotoxic T cells, 155 
which is consistent with their expression of myelin epitopes. Surprisingly, however, 156 
we found that OPCs also exhibited a robust increase in the expression of these 157 
molecules (Fig. 2d), suggesting that OPCs might also be targeted during the disease, 158 
despite not expressing myelin proteins. To validate the expression of MHC-I 159 
molecules in oligodendroglia cells, we have performed RNAscope ISH and observed 160 
an upregulation of B2m molecules in Sox10+ cells in EAE spinal cords as well as the 161 
presence of Psmb9 molecules in Sox10+ cells in EAE that were absent in Sox10+ cells 162 
in control spinal cords (Fig. 2e).  163 
 164 
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MHC-II genes are thought to be restricted to microglia/macrophages in MS, and not 165 
present in OLs in active lesions16. Strikingly, we found the expression of all key genes 166 
required for a MHC-II mediated response, including H2-aa, H2-ab1, H2-eb1, Cd74 167 
and Ctss, in specific subsets of OPCs and OLs (Fig. 3a). To confirm the presence of 168 
these RNA transcripts in OL lineage cells, we performed RNAscope ISH in the EAE 169 
and control spinal cords using probes targeting Cd74 and H2-Eb1 (for MHC-II), in 170 
combination with Aif1 (for microglia), Sox10 (for OL lineage cells), Klk6 (for MOL2) 171 
and Ptprz1 (for OPC) (Fig. 3b-d, Supplementary Fig. 6b, and Supplementary Videos 172 
V1-V6). While we observed microglia processes enwrapping OLs (Supplementary 173 
video V7), a small proportion of OLs/OPCs could be confidently assigned with 174 
double positive Cd74/Sox10 and few or no molecules for Aif1 (Fig. 3d and 175 
Supplementary Videos V1-V6). We also combined RNAscope ISH with 176 
immunohistochemistry and found triple positive OPCs for GFP (from EAE Pdgfra-177 
H2B-GFP spinal cord), Ptprz1 and Cd74 (Fig. 3c and Supplementary video V2). We 178 
also performed IHC for MHC-II and the OL markers OLIG2 and SOX10, and 179 
identified double positive cells for OLIG2/MHC-II and SOX10/MHC-II 180 
oligodendroglia in the spinal cord of EAE mice (Fig. 3e and Supplementary Fig. 6c). 181 
We estimated that in the lesion areas of the white matter SOX10/MHC-II double 182 
oligodendroglia constitute about 3,4% (+/-1,76 SD) of the SOX10+ cells.  We 183 
performed IBA-1 staining to distinguish between SOX10/MHC-II oligodendroglia 184 
and MHC-II expressing macrophages/microglia and we could distinguish the two cell 185 
types. Nevertheless, IBA-1 could still be observed in SOX10/MHC-II oligodendroglia 186 
although with a lower expression, which could be due to induction of some Aif1 187 
molecules (corresponds to IBA-1 protein) in oligodendroglia in EAE, by for instance 188 
interferon-gamma (IFNγ)17. Control CFA-treated spinal cord OPCs/OLs did not 189 
express MHC-II molecules neither at the RNA (RNAscope ISH) nor protein level 190 
(IHC; Fig. 3b and data not shown).  191 
 192 
We found several interferon responsive genes in MHC-II expressing OL/OPC 193 
populations, such as Ifih1, Iigp1, Trim34, Irf7, Irgm1, Irgm2, Igtp and Zbp1 194 
(Supplementary Fig. 7a). It has been shown that IFNγ can trigger endoplasmic 195 
reticulum stress in OLs18. Indeed, we found many genes involved in protein 196 
processing in endoplasmic reticulum differentially expressed in EAE (Supplementary 197 
Fig. 7b). Transcription factors such as Nlrc5, a transactivator of the MHC-I19, was 198 
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expressed upon disease in all OL lineage cells, and Ciita, induced by the IFNγ 199 
pathway and activator of MHC-II genes, was expressed in a subset of these cells 200 
(Supplementary Fig. 4a). Thus, OL/OPC populations in the spinal cord appear to have 201 
the capacity to activate MHC genes upon EAE induction. 202 
 203 
To determine if these populations also occur in human MS, we performed IHC for 204 
MHC-II and the OL markers OLIG2 and OLIG1 in postmortem brain tissue from two 205 
MS patients. As in mouse model EAE, we observed cells in which immune cell-206 
derived MHC-II processes appear to touch/enwrap OLIG2+ nuclei (Supplementary 207 
Fig. 6d arrowheads and Supplementary video V8) but also OLIG2 and OLIG1 cells 208 
positive for MHC-II without any immune cell in their neighborhood (Fig. 3f and 209 
Supplementary Fig. 6d arrows, and Supplementary video V9), indicating that indeed 210 
human OLs can express adaptive immunity proteins in the context of MS. 211 
 212 
Several MS susceptibility variants including MHC and autosomal non-MHC locus 213 
and the associated putative susceptibility genes were recently described1. Comparison 214 
of these loci/genes with RNA-seq from bulk brain led to the inference that peripheral 215 
immune system cells and brain resident microglia were the most likely cell types to 216 
contribute to MS susceptibility1. To examine if MS susceptibility genes were also 217 
expressed in OL lineage cells in EAE, we analyzed the expression of the mouse 218 
homologs for genes associated with the 200 non-MHC, 32 MHC loci, and 19 X-219 
chromosomal loci in our single-cell transcriptomics dataset (Fig. 3g and 220 
Supplementary Fig. 6e and Supplementary Table S4). Interestingly, the MHC-II gene 221 
H2.Aa (human HLA-DQA1) was enriched not only in microglia, but also in EAE-222 
derived OPCs and MOLs (Fig. 3g). Strikingly, several OL lineage cells expressed 223 
non-MHC locus associated susceptibility genes (Fig. 3g and Supplementary Table 224 
S4). This was particular strong for OPCs (importantly both from control and EAE 225 
mice) and MOL1/2-EAE populations (Fig. 3g). OPCs expressed 61% of these genes, 226 
which was in the same range as microglia (67%). Moreover, while we found many 227 
genes are equally expressed in all the populations, there were also genes enriched in 228 
OL lineage cells (such as Bcas1 and Sox8), MOLs (Prr5l), OPCs (such as Kcnh8, 229 
Pkia, Pitpnm2) and microglia (such as Plek; Supplementary Table S4). Interestingly, 230 
a subset of genes starts to be expressed and is upregulated in response to the disease 231 
in MOL populations, in particular MOL1/2-EAE.   232 
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 233 
To investigate the mechanism triggering MHC-II expression in OL lineage cells and 234 
the functional implications in the development of the disease, we performed co-235 
cultures of GFP+ OPCs (from Sox10Cre-GFP mice brains) and CD45+ immune cells 236 
isolated from the spinal cord of EAE mice (Fig. 4a). After 72 hours of co-culture, 237 
4.4% (+/-2.42 SD) of the total GFP+ OPCs in culture were positive for MHC-II (Fig. 238 
4b). We also performed co-cultures of OPCs with CD45+ immune cells from CFA 239 
mice (most likely comprising of microglia/macrophages and few invading leukocytes 240 
from the periphery) and did not find any GFP/MHC-II double positive OPCs in these 241 
conditions (Supplementary Fig. 8a). This indicates that factors secreted by EAE-242 
specific immune cells are inducing MHC-II expression in OPCs. Indeed, while MHC-243 
II expression has been reported to be excluded from OLs in MS16, expression of these 244 
molecules in rat OPCs and OLs has been observed, upon dexamethasone and IFNγ 245 
treatment20. As CD4 lymphocytes such as Th1 and memory T cells are interferon-246 
producing cells, we hypothesized that the observed effect in the co-cultures was 247 
mediated by lymphocyte derived IFNγ. As such, we treated OPCs with IFNγ (100 248 
ng/ml), dexamethasone (1μM) and the combination of both for 3 days (Fig. 4c). We 249 
observed the induction of expression of MHC-II molecules, in OPCs and OLs, only in 250 
IFNγ treated cells, alone or in combination with dexamethasone, both at the RNA 251 
level (RNAscope ISH) and protein level (shown by ICC; Fig. 4d and Supplementary 252 
Fig. 8b-c). We did not find any positive cell for Aif1 RNA molecules in our MACS 253 
OPC primary cultures, nor IBA-1 positive cells, indicating that microglia were absent 254 
and excluding the possibility that MHC-II RNA and protein were derived from 255 
microglia processes. qPCR analysis further confirmed these results. While genes such 256 
as Plin4, were not affected by IFNγ treatment but only to dexamethasone, we 257 
observed a dramatic induction of interferon responsive genes (Ifit2, Ifih1) MHC-II 258 
genes (Cd74) and MHC-II and I transactivators (Ciita, Nlrc5) (Fig. 4e). Thus, our 259 
results indicate that MHC-II genes induction in EAE OL lineage cells is possibly 260 
mediated by IFNγ. 261 
 262 
To uncover the role of immunocompetent OPCs in the disease, we first investigated if 263 
OPCs were capable of phagocytosis, by adding 1μm diameter fluorescent 264 
microspheres to OPC cultures for 24h. OPCs could indeed uptake several 265 
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microspheres, with at least 48% of them exhibiting this capability (Fig. 4f). Moreover, 266 
treatment with the phagocytosis inhibitor cytochalasin D at two different 267 
concentrations for 24 hours, lead to a remarkable reduction in microsphere uptake 268 
(Fig. 4f, g). IFNγ treatment did not alter OPC phagocytic capacity (Fig. 4g). To 269 
further investigate whether OPCs can phagocytise myelin, we incubated OPCs for 6 270 
hours with pHrodo-labeled myelin (a pH-sensitive fluorogenic dye that fluoresce red 271 
in phagosomes21) and found that OPCs were able to uptake myelin as observed by the 272 
red fluorescence staining of live OPCs (Fig. 4f). Altogether, these data demonstrate 273 
that OPCs exhibit phagocytic activity and strongly suggests that OPCs are capable of 274 
taking up myelin debris in a disease context. 275 
 276 
Next, we addressed the impact of MHC-II expressing OPCs on the survival, 277 
proliferation and cytokine production of CD4+ T cells derived from 2D2 mice, where 278 
T cells express the T cell receptor for the MOG35-55 peptide22. OPCs (controls or 279 
pre-treated with IFNγ and/or MOG35-55 peptide) were co-cultured for 72 hours with 280 
either naïve, memory or effector T cells (naïve cells that had been pre-activated in 281 
vitro in the presence of IL-12, acquiring a Th1 phenotype). T cells were subsequently 282 
assessed by flow cytometry for survival (cell dead exclusion), proliferation (Ki67+), 283 
as well as for expression of IFNγ and TNF (Fig. 4h). Co-culturing with non-284 
stimulated OPCs lead to an increase in numbers of surviving naïve, activated and 285 
memory T cells. Survival was further enhanced in memory T cells when OPCs were 286 
pre-treated in IFNγ and MOG peptide suggesting an MHC-II mediated effect (Fig. 4i, 287 
Supplementary Figs. 8e and 9). Regarding proliferation, naïve CD4+ T cells seemed 288 
unaffected by OPC co-culture (Fig. 4j and Supplementary Figs. 8e and 9), as 289 
expected, since these cells have a high threshold of activation provided in secondary 290 
lymphoid tissue. In contrast, we found a higher number of Ki67+ memory CD4+ T 291 
cells when co-cultured with OPCs in the presence of MOG peptide. Similar effects 292 
were observed for Th1 CD4+ T cells which proliferated more in the presence of OPCs 293 
and MOG peptide. These results also suggest that the proliferation effect is via OPC-294 
MOG peptide presentation to memory and Th1 T cells. Of notice, the presence of 295 
MOG peptide, not necessarily together with IFNγ, was enough to induce proliferation. 296 
This indicates that production of IFNγ by memory and Th1 cells may provide a 297 
positive regulatory feedback loop. We thus investigated if the increase in 298 
survival/proliferation was accompanied by cytokine production. Indeed, memory 299 
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CD4+ T cells displayed more cells producing both TNF and IFNγ when co-cultured 300 
with OPCs in the presence of MOG peptide (Supplementary Fig. 8d). In contrast, the 301 
presence of OPCs per se triggered an increase in the number of Th1 CD4+ T cells 302 
producing IFNγ and TNF (Supplementary Fig. 8d).  303 
 304 
OLs are widely seen as a passive target of a dysregulated immune system, but there is 305 
a growing body of evidence of immunomodulatory factors expressed in OLs such as 306 
cytokines/chemokines and their receptors23-27. Our results indicate that both OPCs and 307 
MOLs undergo a transcriptional overhaul during chronic inflammatory 308 
demyelination. The selective expression of immunoprotective, innate and adaptive 309 
immunity genes in OPCs and OLs in EAE suggests potential mechanisms of 310 
protection and an immune function in the context of disease.  Since several of these 311 
genes are susceptibility genes for MS, the OL lineage might have a more central role 312 
in the origin and progression of MS than previously thought. 313 
 314 
OL cell death has been recently shown to lead to an adaptive auto-immune response28, 315 
which could imply an initial dysregulation in cells of the OL lineage as a triggering 316 
event in MS and support the “inside-out” hypothesis for the aetiology of the disease28. 317 
Whether the new identified OL lineage cell states play a role on the aetiology of MS, 318 
by acting as antigen presenting cells and triggering immunologic attack or reinforcing 319 
the disease-initiating event from the periphery, or both, will require further 320 
investigation. In either case, our results indicate that OL lineage cells may not simply 321 
be passive targets of the immune system in MS, but rather central players which may 322 
be targeted in therapeutic approaches for MS. 323 
Accession codes and data availability: A web resource for browsing differential 324 
gene expression data for the single cell data can be accessed at 325 
https://ki.se/en/mbb/oligointernode. Raw data is deposited in GEO, accession number 326 
GSE113973. Code used for single cell RNA-Seq analysis is available at 327 
https://github.com/Castelo-Branco-lab/GeneFocus. 328 
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 461 
Figure legends 462 
Figure 1: Single cell RNA-sequencing of oligodendrocyte (OL) lineage cells in response 463 
to experimental autoimmune encephalomyelitis (EAE) uncovers new disease-specific 464 
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populations and disease markers. a, Schematic overview of the methodology used to 465 
perform single-cell RNA-seq of the OL lineage cells. b, Clinical score of the diseased animals 466 
used in the study (n=12 mice; data represented as mean ± s.e.m.; only animals that reached 467 
score 3 and one that reached score 2.5 were used in this study). c, t-SNE plots of all cells 468 
sequenced showing the segregation of cells derived from Complete Freund's Adjuvant (CFA) 469 
controls and EAE (n=4 biologically independent mouse spinal cord samples per condition; 470 
total number of cells is 794 for controls and 971 for EAE). d, t-SNE plots of all cells 471 
sequenced representing different cell populations within OL lineage cells. Mature 472 
oligodendrocyte (MOL) identities were defined according to marker genes identified in ref. 4 473 
(n=4 biologically independent mouse spinal cord samples per condition; total number of cells 474 
is 745 for controls and 707 for EAE).  e-f, Violin plots depicting the expression of specific 475 
markers for OL precursor cells (OPC) (e) and for MOL clusters  (f) (n=4 biologically 476 
independent mouse spinal cord samples per condition; total number of cells is 116 for OPC 477 
controls and 132 for OPC EAE and 626 for MOL controls and 575 for MOL EAE). Violin 478 
plots are centered around the median with interquartile ranges and shape represents cell 479 
distribution. g, t-SNE plots of disease-specific markers for OL lineage cells (n=4 biologically 480 
independent mouse spinal cord samples per condition; total number of cells is 745 for 481 
controls and 707 for EAE). h, Schematic representation of the exon 6 inclusion in the Pdgfa 482 
gene in response to EAE. i, Violin plot representing the PSI (proportion of spliced isoform) in 483 
controls (MOL2 Ct-a depicted in green) and EAE (MOL1/2 EAE depicted in purple) of the 484 
alternative spliced exons in Pdgfa and Mbp genes. PSI=0 means totally excluded and PSI=1 485 
totally included (n=4 biologically independent mouse spinal cord samples per condition; total 486 
number of cells is 56 for MOL2 Ct-a and 49 for MOL1/2 EAE; Pdgfa ex6: p=0.0003176 and 487 
Mbp ex2: p=5.323e-11 by two-sided Wilcoxon rank sum test with continuity correction; 488 
Violin plots are centered around the median with interquartile ranges and shape represents 489 
cell distribution. VLMCs - vascular and leptomeningeal cells; MiGl - Microglia-like cells. 490 
 491 
Figure 2: Expression of immunoprotective and adaptive immunity genes in response to 492 
EAE. a, RNAscope ISH representing a spinal cord from CFA control and EAE mice marked 493 
with probes for Sox10, Klk8 and Hopx, markers of MOL1/2-EAE. Dashed boxes shown at 494 
higher magnification highlight regions with higher densities of MOL1/2 cells. Arrows depict 495 
triple positive cells in EAE and arrowheads depict Hopx positive OL lineage cells negative 496 
for Klk8. Representative images, n=3 biologically independent mouse spinal cord samples. 497 
Scale bars - 20μm b, Violin plots representing Serpina3 family of genes in OL lineage cell 498 
populations derived from CFA controls and EAE mice. (n=4 biologically independent mouse 499 
spinal cord samples per condition; total number of cells is 745 for controls and 707 for EAE). 500 
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Violin plots are centered around the median with interquartile ranges and shape represents 501 
cell distribution.  c, RNAscope ISH representing a spinal cord from CFA control and EAE 502 
mice marked with probes for Sox10 and Serpina3n. Representative images, n=3 biologically 503 
independent mouse spinal cord samples. Scale bars - 20μm. d, Violin plots representing MHC 504 
class I related genes in OL lineage cell populations derived from CFA controls and EAE 505 
mice. (n=4 biologically independent mouse spinal cord samples per condition; total number 506 
of cells is 745 for controls and 707 for EAE). Violin plots are centered around the median 507 
with interquartile ranges and shape represents cell distribution. e, RNAscope ISH 508 
representing a spinal cord from CFA control and EAE mice marked with probes for Sox10, 509 
and MHC-I related genes, Psmb9 and B2m. Arrows depict triple positive cells, arrowheads 510 
depict cells double positive for Psmb9/B2m and negative for Sox10 that do not belong to the 511 
OL lineage. Representative images, n=3 biologically independent mouse spinal cord samples, 512 
scale bars - 20μm. 513 
 514 
Figure 3: Expression of MHC class II and MS susceptibility genes in the OL lineage cells 515 
in response to EAE and in MS. a Violin plots representing MHC class II related genes in 516 
OL lineage cell populations derived from CFA controls and EAE mice. (n=4 biologically 517 
independent mouse spinal cord samples per condition; total number of cells is 745 for 518 
controls and 707 for EAE). Violin plots are centered around the median with interquartile 519 
ranges and shape represents cell distribution. b-d, RNAscope ISH representing spinal cords 520 
from CFA control and EAE mice marked with probes for MHC-II (Cd74), OL lineage cells 521 
(Sox10 and Ptprz1/Pdgfra-H2B-GFP specific for OPCs) and microglia (Aif1). Dashed boxes 522 
shown at higher magnification represent both OL lineage cells expressing MHC-II 523 
(arrowhead), and microglia cells expressing MHC-II (arrow). Representative images, n=3 524 
biologically independent mouse spinal cord samples per condition, scale bars - 20μm. e, 525 
Immunohistochemistry showing OL lineage cells (positive for Sox10) co-expressing MHC-II 526 
protein, in a lesion in the spinal cord of EAE mice. Representative images, n=3 biologically 527 
independent mouse spinal cord samples per condition, scale bars - 20μm. f, 528 
Immunohistochemistry in human samples from two MS patients representing OLIG1 positive 529 
OLs expressing MHC-II (arrows). Representative images, n=2 biologically independent 530 
human brain samples. Scale bars - 25μm. g, Expression-based heat maps for the MS 531 
susceptibility genes (from ref. 1) in microglia and OL lineage cells. MHC locus and non-532 
MHC locus related genes are represented in both microglia and all OL lineage cells 533 
populations analyzed in this study. 534 
Figure 4: OPCs express MHC-II in response to interferon-γ, exhibit phagocytic capacity 535 
and regulate T cell survival and proliferation. a, Schematic representation of co-culture 536 
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between OPCs isolated from Sox10-Cre-GFP mice and CD45+ immune cells isolated from 537 
EAE mice or CFA controls. b, Immunohistochemistry showing OL lineage cells (positive for 538 
Sox10) co-expressing MHC-II protein, but not the microglia marker IBA1, upon co-culture 539 
with CD45+ immune cells from EAE mice. Representative images, n=3 independent 540 
experiments, scale bars - 20μm. c, Schematic representation of treatment of OPCs and OLs 541 
with interferon-γ (100 ng/ml) and dexamethasone (1μM). d, OLs cultured with 542 
dexamethasone and interferon-γ for 72h express MHC-II as represented by Cd74/Sox10 and 543 
MHC-II/CNP double staining in RNAscope ISH and immunocytochemistry, respectively. 544 
Representative images, n=3 independent experiments. Scale bars - 20μm. e, qRT-PCR 545 
analysis for MHC and interferon responsive genes on primary OPCs and OLs treated with 546 
interferon-γ and dexamethasone, n=3 independent experiments per condition; data 547 
represented as mean ± s.d. f, Uptake of pHrodo-labeled myelin and 1μm diameter fluorescent 548 
microspheres by primary NG2+ OPCs after 6 and 24 hours, respectively, and upon treatment 549 
with 50μM of cytochalasin D. Representative images, n=3 independent experiments. Scale 550 
bars - 20μm. g, Quantification of the percentage of OPCs uptaking microspheres in the 551 
presence or absence of IFN−γ (100 ng/ml) and upon treatment with 20 and 50μM of 552 
cytochalasin D. n=3 independent experiments per condition; data represented as mean ± s.d. 553 
h, Schematic representation of co-culture between primary OPCs, treated with interferon-γ 554 
and/or MOG 35-55 peptide, and three different types of CD4 lymphocytes (naïve, memory 555 
and activated Th1) from 2D2 transgenic mice, where a high proportion of CD4 T-556 
lymphocytes express a T-cell receptor specific for MOG35-55 peptide. i-j, Graph plots 557 
obtained from FACS analysis of naïve, memory and activated Th1 2D2 CD4 T cells after 72 558 
hours of co-culture with OPCs. General survival (dead cell exclusion marker) and 559 
proliferation (CD4+ Vβ11+ Ki67+) were assessed. Numbers of cells in the live gate as well as 560 
in the Ki67+ gate were estimated and reflect survival and proliferation since the same cell 561 
numbers were seeded onto different wells. Plots represent the averages of the assessed values 562 
for the different conditions divided by the values of the control (T cells only) for fold change 563 
differences. n=7 independent experiments; data represented as mean ± s.e.m. 564 
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ONLINE METHODS 565 
Information regarding methods used in this paper can be found below and also in the Life 566 
Sciences Reporting Summary. 567 
 568 
Animals. Mouse lines used in this study included C57BL/6NJ wild type (WT) mice, Pdgfra-569 
Cre-LoxP-GFP7, Pdgfra-H2B-GFP knock-in mice6, Sox10Cre-LoxP-GFP29 and C57Bl/6 2D2 570 
transgenic mice22.  Pdgfra-Cre-LoxP-GFP mice are a strain of mice obtained originally by 571 
crossing mice with Cre recombinase under the control of a Pdgfra genomic DNA fragment 572 
(with a C57BL/6NJ genetic background; The Jackson Laboratories, CA, USA) with reporter 573 
mice RCE:loxP-GFP  (with CD1 background; Gord  Fishell,  NYU  Neuroscience  Institute)  574 
to  label  the  complete  OL lineage. Sox10-Cre-LoxP-GFP mice are a strain of mice obtained 575 
originally by crossing mice with Cre recombinase under the control of the Sox10 promoter 576 
(The Jackson Laboratories, CA, USA; with a C57BL/6 genetic background) with reporter 577 
mice RCE:loxP-GFP  (with CD1 background) to  label  the  complete  OL lineage. Pdgfra-578 
H2B-GFP, with a C57BL/6NJ background, presents an H2B-eGFP fusion gene expressed 579 
under the promoter of the OPC marker, Pdgfra. Mice homozygous for the knock-in targeted 580 
mutation have an embryonic lethal phenotype, with half of the embryos failing to survive past 581 
embryonic day 12.5 and the remainder failing to survive beyond embryonic day 15.5 582 
(https://www.jax.org/strain/007669). Only heterozygote mice were used, in which Pdgfra is 583 
expressed mainly in OPCs but also in some extent in the early stages of OL differentiation, 584 
due to GFP half-life. Animals were used in adult stage, between 10-12 weeks old and both 585 
genders were included. The following light/dark cycle was used: dawn 6.00-7.00; daylight 586 
07.00-18.00; dusk 18-00-19.00; night 19.00-06.00. A maximum of 5 adult mice per IVC-cage 587 
of type II Allentown. Breedings were done with 1 male and up to 2 females. All experimental 588 
procedures performed followed the guidelines and recommendations of local animal 589 
protection legislation and were approved by the local committee for ethical experiments on 590 
laboratory animals in Sweden (Stockholms Norra Djurförsöksetiska nämnd). 591 
 592 
Experimental Autoimmune Encephalomyelitis (EAE). For the induction of chronic EAE, 593 
animals were injected subcutaneously with an emulsion of MOG35-55 in complete Freud’s 594 
adjuvant (CFA; EK-2110 kit from Hooke Laboratories) followed by the administration of 595 
pertussis toxin in PBS (0,2μg per animal), for two consecutive days (all according to 596 
manufacturer’s instructions). Spinal cords and cerebellum were collected at the peak/chronic 597 
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stage of the disease with clinical score=3 representing limp tail and complete paralysis of hind 598 
legs. Animals that did not reach this clinical score were not analyzed in this study. Additional 599 
animals were injected subcutaneously with a CFA emulsion (CK-2110 kit from Hooke 600 
Laboratories) and analyzed as controls. 601 
 602 
Tissue dissociation for single-cell RNA sequencing, FACS analysis and sequencing data 603 
processing. Cells were isolated from the spinal cord of P90 Pdgfra-H2B-GFP and Pdgfra-604 
Cre-LoxP-GFP mice. Tissue was then dissociated into a single cell suspension, as previously 605 
described in Marques et al 2016, with some modifications.  Mice were perfused with 606 
oxygenated cutting solution (87 mM, NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 26 mM 607 
NaHCO3, 75 mM sucrose, 20 mM glucose, 1 mMCaCl2, and 2 mM MgSO4) and the brain 608 
was quickly dissected and dissociated using the Adult brain dissociation kit from Miltenyi 609 
(130-107-677) following the manufacturer’s instructions (red blood cells removal step was 610 
not included). After debris removal, cell suspension was filtered with 30μm filter (Partec) and 611 
processed by FACS. Spinal cord single GFP+ cells were selected in a BD Influx sorter and 612 
collected into a 384 plate for SmartSeq2, according to procedures described in5. SmartSeq2 613 
raw data was processed according to procedures described in5. Smart-seq2 paired-end reads 614 
were trimmed with cutadapt 1.8.030 and aligned with STAR 2.5.1b31 to mm10 genome 615 
assembly, only uniquely mapped reads were used for downstream analyses.    616 
 617 
Primary OPC cell culture. Mice brains from P7 pups were removed and dissociated in 618 
single-cell suspensions using the Neural Tissue Dissociation Kit (P; Miltenyi Biotec, 130-619 
092-628) according to the manufacturer’s protocol. OPCs were obtained with MACS with 620 
CD140a microbeads following the manufacturer’s protocol (CD140a Microbead kit, Miltenyi 621 
Biotec 130-101-547). Alternatively to MACS, GFP+ OPCs derived from Sox10-GFP mice 622 
were collected with FACS following brain dissociation. Cells were seeded in poly-L-lysine 623 
(O/N; Sigma P4707) plus fibronectin (1h; Sigma F1141) coated dishes and grown on 624 
proliferation media comprising DMEM/Gmax (ThermoFisher Scientific 10565018), N2 625 
media (ThermoFisher Scientific 17502048), Pen/Strep (ThermoFisher Scientific 15140122), 626 
NeuroBrew (Miltenyi 130-093-566), bFGF 20ng/ml (Peprotech 100-18B) and PDGF-AA 627 
10ng/ml (Peprotech, 100-13A). For OPC differentiation, cells were left for 2 days in medium 628 
without bFGF and PDGF-AA. Cells were treated either with Dexamethasone (1μM), 629 
Interferon-gamma (100ng/mL; R&D, 485-MI-100) or the combination of the two for 72 630 
hours. For the phagocytosis experiments, 1μL per ml of media of pHrodo-labeled myelin and 631 
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0.5μL per ml of media of Fluoresbrite® Polychromatic Red Microspheres 1μm (Polysciences, 632 
Inc, 18660-5) were added to OPCs for 6h and 24h, respectively. Hoechst (ThermoFisher 633 
Scientific, 62249) was added at a dilution 1:1000 to OPCs incubated with pHrodo-labeled 634 
myelin for live-cell fluorescent staining of the DNA and nuclei. Phagocytosis inhibition 635 
experiments were performed by adding two different concentrations of cytochalasin D  636 
(Sigma, C8273) 20μM and 50μM in the presence or absence of Interferon-gamma 637 
(100ng/mL) for 24 hours. Cells were thoroughly washed before fixation. 638 
pHrodo-labeled myelin preparation: myelin sheaths were obtained by dissection and 639 
mechanical homogenization of PBS perfused mouse brains. Pure myelin was then isolated by 640 
several steps of density separation by ultra-centrifugation in sucrose solutions32,33.  After 641 
several cleaning steps we incubated the purified myelin with pHrodo red (Thermo Fisher, 642 
P36600) for 30 minutes following the manual instructions, followed by extensive washing in 643 
PBS/Hepes.   644 
 645 
 646 
OPC/CD45+ EAE co-culture experiments. 647 
CFA and EAE mice were perfused in PBS and the spinal cords were collected. Immune cells 648 
(lymphocytes, monocytes and macrophages) were then isolated using the adult Brain 649 
Dissociation Kit (Miltenyi Biotec, 130-107-677) according to the manufacturer’s protocol and 650 
collected with MACS with CD45+ microbeads (CD45 Microbead kit, Miltenyi Biotec 130-651 
052-301) according to the manufacturer’s protocol. CD45+ cells (150-200,000) were added on 652 
top of cultured OPCs (300,000 cells) and incubated for 72hours. 653 
 654 
OPC/T cell co-culture experiments. 655 
Naïve and memory T cells were isolated from C57Bl/6 2D2 transgenic mice that express a 656 
TCR specific for the MOG 35-55 peptide22. Splenocytes were isolated by tissue disruption 657 
through a 100μm mesh and erythrocytes were lysed with ACK buffer (Invitrogen). 658 
Splenocytes were depleted from all non-T cells using a naive CD4+ T cell Isolation Kit (130-659 
104-453; Miltenyi), and the flow through was further sorted into CD44 low (naïve) and CD44 660 
high (memory) cells using anti-CD44 beads from the same kit. Cells were frozen in FCS 661 
containing 10% DMSO for subsequent experiments. Activated T cells were generated from 662 
naïve cells stimulated in vitro with plate-bound anti-CD3 (BD; 555273; 2μg/ml) and soluble 663 
anti-CD28 (BD; 553294; 1μg/ml) in the presence of 10ng/ml IL-12 (R&D Systems, 419-ML) 664 
for 3 days, followed by 3 days expansion in 10ng/ml IL-2 (R&D Systems, 402-ML) and 665 
 
20
cytokine starvation for 24h prior to co-culture (at the exception of one n which was not 666 
deprived from cytokines). 667 
OPCs (6 n’s obtained with MACS and one n with FACS of GFP+ cells from Sox10-GFP 668 
mice) were seeded at a density of 20,000 cells per well in a 96-well plate and pre-treated with 669 
interferon-gamma (100ng/mL) and/or MOG 35-55 peptide (Anaspec, AS-60130-5) at 670 
40μg/ml for 72hours. Cells were washed twice in PBS. Naïve, memory and activated T cells 671 
were both seeded alone (with or without MOG 35-55 peptide at 40μg/ml) and on top of 672 
control or stimulated OPCs at 2x105 cells/well in 96 well plates with MOG 35-55 peptide at 673 
40μg/ml and incubated at 37°C. Media used for T cells as well as for T cell:OPC co-culture 674 
was RPMI (Sigma, R8758), 10% FBS (v/v; Sigma F7524), Penicillin-Streptomycin (Sigma, 675 
P4458, 100 U/ml). After 72h, cells were stimulated for 5h at 37°C in media containing 676 
50ng/ml PMA (Sigma, P1585), 1μg/ml Ionomycin (Sigma, I0634) and 1μg/ml GolgiPlug 677 
(BD, 555029), to boost cytokine secretion, followed by staining for CD4 PE-Dazzle 678 
(BioLegend, 100566),  Ki67 V450 (BD, 561281), anti-TCR Vbeta11 BV510 (BD, 743677), 679 
TNF PE-Cy7 (eBioscience, 25-7423-82), IFNg APC (BD, 554413) as well as dead cell 680 
exclusion dye near-IR (Invitrogen, L10119). Surface staining at 4°C for 30 minutes was 681 
followed by fixation and permeabilization using an intracellular staining kit (eBioscience, 88-682 
8824-00), followed by intracellular staining. For the relative assessment of cell survival and 683 
proliferation, samples were resuspended in equal volume and acquired by fixed time with a 684 
Gallios Flow Cytometer (Beckman Coulter) and analyzed using a Kaluza Flow Cytometry 685 
Analysis Software (Beckman Coulter). Numbers of cells in the live gate as well as in the 686 
Ki67-positive gate reflect survival and proliferation since the same cell numbers were seeded 687 
onto different wells. All conditions were run in three biological replicates for each of the 688 
seven experiments. Averages of the assessed values for the different conditions were divided 689 
by the values of the control (T cells only) for fold differences.  690 
 691 
RNA extraction, cDNA synthesis and quantitative real-time PCR (qRT-PCR). Spinal 692 
cord and cerebellum were collected from WT control and EAE mice. OPCs and OLs from in 693 
vitro cultures were collected in 700μl Qiazol. RNA was extracted with the miRNeasy 694 
microkit (Qiagen, 217084) according to manufacturer’s protocols. Contaminating DNA was 695 
degraded by treatment of the samples with RNase-free DNase (Qiagen, 79254) in column. 696 
0.35-1µg of RNA from each sample was reversed transcribed for 1h with the High-Capacity 697 
cDNA Reverse Transcription Kit (Applied Biosystems, 4368813) including RNase inhibitor 698 
(Applied Biosystems, N8080119). A reverse transcriptase negative (RT-) control was 699 
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included for each sample. Both the cDNA and the RT- were diluted 1:5 in RNase/DNAse free 700 
water for qRT-PCR.  701 
qRT-PCR reactions were run on a StepOnePlus™ System (Applied Biosystems) in duplicate 702 
and with RT- reactions to control for genomic DNA. Fast SYBR® Green Master Mix 703 
(Applied Biosystems, 4385616) was used according to the manufacturer’s instructions, each 704 
PCR reaction had a final volume of 10μl and 1–2.5μl of diluted cDNA or RT-. The running 705 
conditions were 20 seconds at 95˚C, followed by 40 cycles of 3 seconds of 95˚C and 30 706 
seconds of 60˚C, then 15 seconds at 95˚C, 1 minute at 60˚C and 15 seconds at 95˚C. A 707 
melting curve was obtained for each PCR product after each run, to control for primer dimers 708 
and gene-specific peaks. Tbp and Gapdh were run as housekeeping genes. Relative standard 709 
curves were generated for each gene to determine relative expression (CT values are 710 
converted to arbitrary quantities of initial template per sample). Expression levels were then 711 
obtained by dividing the quantity by the value of the geometric mean of the housekeeping 712 
genes. PCR primers sequences (design according 34) used are the following: Pdgfa short (F: 713 
CGTCAAGTGCCAGCCTTC and R: GCACACTCCAGGTGTTCCTC), Pdgfa long (F: 714 
TGAAAGAGGTCCAGGTGAGG and R: CCTTTTCCTTTTCCGCTTTT), Mbp exon2 (F: 715 
GCTTCTTTAGCGGTGACAGG and R: CCTTGTACATGTGGCACAGC), Mbp exon1 (F: 716 
TGGCCACAGCAAGTACCAT and R: AGTCAAGGATGCCCGTGT), Tbp (F: 717 
GGGGAGCTGTGATGTGAAGT and R: CCAGGAAATAATTCTGGCTCA), Gapdh (F: 718 
GAGAAACCTGCCAAGTA and R: AGACAACCTGGTCCTCA), Cd74 (F: 719 
CTGGATGAAGCAGTGGCTCT and R: CCCAGGCCAGAAGATAGGTC), Ciita (F: 720 
CTGGCACAGGTCTCTCCAGT and R: TACTGAGGCTGCTTGAAGGG), Nlrc5 (F: 721 
CCGTGGTACTCACATTTGCC and R: CCTTCGAGATCTCTGGGACA), Ifit2 (F: 722 
AAGGCAGAGGAAGAGGTTGC and GTCGCAGATTGCTCTCCAGT), Ifih1 (F: 723 
ATGTCTTGGACACTTGCTTCG and R: CTGACTCATTCCCGCTGTTT) and Plin4 (F: 724 
ACACAGTGGCCACAGGACTT and R: GGTCACCGTGTCCTTAGTGC). 725 
 726 
Tissue processing for Immunofluorescence and RNAscope ISH. For 727 
immunohistochemistry and RNAscope ISH mice were perfused with PBS followed by 4% 728 
PFA. Spinal cords from EAE and control mice were dissected and post-fixed with 4% PFA 729 
for 1h, at 4ºC. The tissues were embedded into OCT (Tissue-Tek), frozen in dry ice and 730 
sectioned coronally (20 μm thickness). Sections were stored at –80°C. 731 
For immunocytochemistry and RNAscope ISH in cultured cells, cells were fixed in 4% 732 
formaldehyde for 10 minutes and washed in PBS.  733 
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 734 
Immunohistochemistry and immunocytochemistry (mouse and human samples). For 735 
immunocytochemistry cells were incubated overnight at 4ºC with the following primary 736 
antibodies: CNP (Abcam ab6319, Mouse 1:200), MHC-II (anti-I-A/I-E; BD Bioscience rat 737 
1:600), GFP (Abcam ab13970, Chicken 1:1000), NG2 (Millipore AB5320, Rabbit 1:200), 738 
IBA-1 (Wako 019-19741, rabbit 1:400) in PBS/0.5%Triton/10% normal donkey serum 739 
(Sigma, D9663). Cells were washed with PBS and then incubated for 2 hours with Alexa 740 
Fluor-conjugated antibodies (Invitrogen). 741 
Spinal cord sections were incubated overnight at 4ºC in the following primary antibodies: 742 
OLIG2 (R&D, Goat 1:200), SOX10 (R&D, Goat 1:100), PLIN4 (Sigma, Rabbit 1:200), IBA-743 
1 (Wako 019-19741, rabbit 1:400) and MHC-II (anti-I-A/I-E; BD Bioscience rat 1:600) 744 
diluted in PBS/0.5% Triton/10% normal donkey serum. After washing the section with PBS, 745 
secondary Alexa Fluor-conjugated antibodies (Invitrogen) diluted in PBS/0.5% Triton/10% 746 
normal donkey serum were incubated for 2h at room temperature. Slides were mounted with 747 
mounting medium containing DAPI (Vector, H-1200) and kept at 4ºC until further 748 
microscopic analysis. Images from sections were taken of the spinal cord using a Zeiss 749 
LSM700 Confocal, and processed in ImageJ. 750 
Human brain 4μm paraffin sections, from regions with high microglia activity (thus active 751 
lesions) were dewaxed in a descending EtOH-row. After antigen retrieval and endogenous 752 
peroxidase quenching, they were incubated over night at 4 degrees with the following primary 753 
antibodies: OLIG1 (Abcam, 68105, 1:100), OLIG2 (Atlas, HPA003254, 1:200) and MHC-II 754 
(Dako, M0775 1:100) diluted in TBS/0.3% Triton/20% normal horse serum. After washing 755 
with TBS/0.001% Triton, they were incubated for 1 hour at room temperature with Goat F(ab) 756 
Anti-Rabbit IgG H&L (HRP) and Goat F(ab) Anti-Mouse IgG H&L (HRP; ab7171 and 757 
ab6823 abcam, 1:500).  After washing in TBS/0.001% Triton, the fluorescence was visualized 758 
with the tyramide kits from Perkin Elmer (NEL745B001KT and NEL744B001KT). The 759 
human tissue used in this study comprised one female and one male, with ages of 38 and 50 760 
years old both with secondary progressive multiple Sclerosis. No patient had specific disease 761 
treatment. Post mortem MS tissue was provided via a UK prospective donor scheme with full 762 
ethical approval from the UK Multiple Sclerosis Tissue Bank (MREC/02/02/39). 763 
 764 
RNAscope ISH. RNAscope ISH was performed on cultured cells and spinal cord sections 765 
from controls and EAE mice with probes for mouse Cd74, H2-Eb1, Aif1, Sox10, Klk6, Hopx, 766 
Ptpzr1, Serpina3n, B2m, Psmb9 and Klk8 all purchased from ACD.  RNAscope ISH protocol 767 
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for sections was performed following manufacturer’s instructions with minor modifications 768 
(ACD, RNAscope® Multiplex Fluorescent Detection Reagents v2 Cat. No.323110). Briefly, 769 
sections were placed on a hot plate (100°C) with 1x target retrieval (Pretreatment Reagents 770 
Cat. No. 322381 and 322000) for 5 min followed by 2 steps of washes of 2 min and 1 wash 771 
with 100% ethanol for 2min. Protease IV was applied on top of the sections and incubated for 772 
20min at RT followed by 2 washes of 2 min each. Probes were diluted 1:50 in the C1 probe, 773 
hybridized for 2h at 40°C and washed twice in wash buffer (RNAscope® Wash Buffer 774 
Reagents Cat. No. 310091). Amplification steps were performed by incubating with v2Amp1 775 
(30min), v2Amp2 (30min) and v2Amp3 (15min) at 40°C with washes of 2x2min in between 776 
steps (RNAscope® Multiplex Fluorescent Detection Reagents v2 Cat. No. 323110). Sections 777 
were incubated v2HRP-C1 for 15min at 40°C and washed twice in wash buffer for 2min. 778 
TSA conjugated fluorophores were diluted in 1:1500 in TSA buffer (RNAscope® Multiplex 779 
TSA Buffer Cat. No. 322809) and incubated for 30min at 40°C followed by 2 washes of 2min 780 
and HRP blocker incubation for 30min at 40°C. The last steps were performed subsequently 781 
for v2HRP-C2 and v2-HRP-C3. To combine the RNAscope ISH with immunofluorescence 782 
for GFP, sections were further blocked in block with 5% NDS in 0.3% PBS-Tx100, 1h, RT 783 
and incubated with chicken anti-GFP (abcam, ab13970 1:200,) overnight at 4°C. Sections 784 
were further incubated with goat anti-chicken (Alexa Fluor 488 1:500) for 2h at RT and with 785 
DAPI (1:5000) for 2 min.  786 
 787 
Confocal Microscopy and cell counting. Images from sections of both Immunofluorescence 788 
and RNAscope ISH were acquired for the spinal cord using a Zeiss LSM700 Confocal, and 789 
processed in Fiji/ImageJ. Images from the human tissue were acquired using a Leica SP8 790 
Confocal, Images were processed in Fiji/ImageJ. Estimation of the percentage of the double 791 
MHC-II/SOX10 positive cells in the spinal cord of EAE mice was performed by counting the 792 
double positive cells present in the lesion areas of the white matter divided by the total 793 
SOX10+ cells. The final percentage is represented as an average of 3 EAE mice. For the co-794 
cultures the number of GFP/MHC-II double positive cells were divided by the total number of 795 
GFP+ cells. The final percentage is represented as an average of 3 independent experiments. 796 
For estimation of the percentage of OPCs that phagocyte microspheres, only OPCs with more 797 
than 10 microspheres surrounding the nucleus were considered as phagocytic OPCs. While 798 
this might have led to an underestimation of phagocytic OPCs, this way we have avoided 799 
counting OPCs with adherent and extracellular microspheres as phagocytic OPCs.  Videos 800 
were obtained from z-stacks after processing with Imaris image analysis software.  801 
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 802 
Supplementary Video information 803 
Movie 1: MOL2 cells express MHC-II genes. RNAscope ISH representing a mouse spinal 804 
cord from EAE mice marked with probes for Cd74 (red dots) and Klk6 (green dots). A double 805 
positive cell is further highlighted in the video and represents an MOL2 cell expressing MHC-806 
II. 807 
Movie 2: OPCs express MHC-II genes. RNAscope ISH representing a mouse spinal cord 808 
from EAE mice marked with probes for Cd74 (red dots), nuclear GFP (from Pdgfra-H2B-809 
GFP knock-in mice labeling OPCs) and Ptprz1 (white dots). A triple positive cell is further 810 
highlighted in the video and represents an OPC expressing MHC-II. 811 
Movie 3: OL lineage cells express MHC-II genes. RNAscope ISH representing a mouse 812 
spinal cord from EAE mice marked with probes for Cd74 (red dots), Sox10 (green dots) and 813 
Aif1 (white dots). A double positive cell is further highlighted in the video and represents an 814 
OL lineage cell expressing MHC-II.  815 
Movie 4: OL lineage cells express MHC-II genes. RNAscope ISH representing a mouse 816 
spinal cord from EAE mice marked with probes for Cd74 (red dots), Sox10 (green dots) and 817 
Aif1 (white dots). A double positive cell is further highlighted in the video and represents an 818 
OL lineage cell expressing MHC-II.  819 
Movie 5: OL lineage cells express MHC-II genes and few Aif1 molecules. RNAscope ISH 820 
representing a mouse spinal cord from EAE mice marked with probes for Cd74 (red dots), 821 
Sox10 (green dots) and Aif1 (white dots). At least 2 double positive cells are further 822 
highlighted in the video and represent an OL lineage cells expressing MHC-II and few Aif1 823 
molecules.  824 
Movie 6: OL lineage cells express MHC-II genes. RNAscope ISH representing a mouse 825 
spinal cord from EAE mice marked with probes for H2.eb1 (red dots) and Sox10 (green dots). 826 
A double positive cell is further highlighted in the video and represents an OL lineage cell 827 
expressing MHC-II. 828 
Movie 7: Microglia processes touch OL lineage cells. RNAscope ISH representing a mouse 829 
spinal cord from EAE mice marked with probes for Cd74 (red dots), Sox10 (green dots) and 830 
Aif1 (white dots). A microglia-derived process touching an OL lineage cell is further 831 
highlighted in the video.  832 
Movie 8: MHC-II positive cells surround OL lineage cells in human MS patient samples. 833 
IHC performed in human brain tissue from one MS patient marked with antibodies for MHC-834 
II (white) and OLIG1 (green). A MHC-II positive cell that resides between two OLIG1 835 
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positive cells is further highlighted.  836 
Movie 9: OL lineage cells from human MS patient samples express MHC-II genes. IHC 837 
performed in human brain tissue from one MS patient marked with antibodies for MHC-II (white) and 838 
OLIG1 (green). A double positive cell representing an OL lineage cell expressing MHC-II is further 839 
highlighted in the video.  840 
 841 
 842 
Clustering analysis using GeneFocus pipeline. 843 
Quality Control. Cells were clustered using a custom-made approach, which we developed 844 
and refer as GeneFocus. We generated an iterative Level 1 and Level 2 clustering pipeline, 845 
taking advantage of diffusion mapping and spatial autocorrelation metrics to define relevant 846 
genes and cell clusters. First cells were analysed and quality control (QC) filtering was 847 
applied using the scater 1.6.0 in R. We applied cut-offs for the expression level 200000 total 848 
FPKM and number of genes expressed 2500, resulting in 2304 and 1777 cells pre- and –post 849 
QC respectively. Median FPKM values were 395721, and median gene counts were 3694 850 
genes. 851 
 852 
Spatial Gene-filtering. Cells were normalized (see supplemental code in Github) and feature 853 
selection was performed using a support vector model from the e1071 R package 854 
(https://CRAN.R-project.org/package=e1071). The resulting expression matrix was then inputted into 855 
a custom pipeline performing iterative gene-filtering in the following manner: we converted 856 
the expression matrix into a transition matrix using destiny 2.6.1 in R35 with the input being 857 
the first 30 principal components of the expression matrix. Subsequently, a distance matrix 858 
was created from the transition matrix, after which the MoransI autocorrelation metric was 859 
computed for each gene using the spdep 0.6-15 R package36. Genes were filtered according to 860 
the mean MoransI computed for all the genes in the expression matrix, and this mean MoransI 861 
was set as a general threshold for subsequent gene filtering. After this initial filtering, a new 862 
diffusion map was computed and we iteratively repeated this process until all genes within the 863 
gene set remained above the determined threshold of spatial correlation set during the first 864 
round of gene filtering. A similar approach was performed using the transition matrix as a 865 
distance metric. A cut-off value was calculated using a support vector model that predicts a 866 
mean distance as a function of the population size in which the gene is expressed and the 867 
mean distance observed. We iterated the distance matrix until we obtained a gene set equal or 868 
smaller than the covered gene set obtained from the MoransI metric. A joint diffusion map 869 
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was then created. 870 
 871 
Level 1 Clustering. Level 1 clustering was established by estimating the ideal number of 872 
clusters by silhouette width using the principal components of the transition matrix, from 873 
which the number was estimated on the basis of an elbow plot. We estimated clusters using 874 
the factoextra 1.0.5 package (https://CRAN.R-project.org/package=factoextra) and hierarchical 875 
clustering using Wards metric. We determined 5 initial clusters representing OPCs and early 876 
OLs, MOLs, VLMCs and pericytes, and microglial cells. 877 
 878 
Level 2 Clustering. To determine more specific clustering and relevant genes we performed 879 
the iterative gene filtering on each of the subclusters. The threshold for the MoransI metric 880 
was established to be the mean MoransI of the gene set resulting from the second gene 881 
filtering round. This resulted in a final gene set for each sub-cluster varying between 800-882 
1000 spatially correlated genes per Level 1 sub-cluster. Clusters were estimated by silhouette 883 
width and the final clustering was evaluated using the resulting heatmap of the filtered genes. 884 
For validation of the GeneFocus pipeline, we extracted the expression information from GEO 885 
from37 and were able to identify the disease-associated microglia cluster previously 886 
described37  (Supplementary Fig. 2). To achieve out final clustering result, we also removed 887 
cells that were clustered in clusters with less than 3 cells, resulting in a total number of 1765 888 
cells. These cells seemed to be doublets based on mixed expression profiles. 889 
 890 
Gene Modules. To generate the gene-modules, we performed non-negative matrix 891 
factorization, where ranks were established using a measure of mutual information with the 892 
elbow method. We established that 30 ranks were the optimal rank to decompose the dataset 893 
in. To only select robust components from the decomposed matrix, we performed PCA on the 894 
components and established an optimal k number of clusters based on wards metric. All 895 
component values falling within a cluster were summed after which the new concatenated 896 
components were filtered based on a threshold of a Pearson correlation of 0.5 with any gene 897 
in the dataset. This resulted in 15 components that revealed the major gene trends underlying 898 
the data. 899 
 900 
Differential expression and pathway visualization 901 
Differential expression analysis was performed using the MAST R package v1.4.138. Pathway 902 
visualization was performed using the clusterProfiler package v3.6.039. 903 
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 904 
Comparison between OPCs in the current dataset and OPCs during development4. The 905 
R package MetaNeighbor was used, found at (https://github.com/maggiecrow/MetaNeighbor).906 
  907 
 908 
Gene ontology and pathway analysis. Most significantly differentially expressed genes were 909 
selected for each of the GO analyses. For each cell type, unique top differentially upregulated 910 
genes in EAE and unique top differentially upregulated genes in controls were selected. For 911 
comparisons between cell types, uniquely differentially expressed genes for each cell category 912 
were selected. In order to make gene sets comparable, top 100 genes were selected. GO and 913 
pathway analysis was performed with Cytoscape 3.5.140 plug-in  ClueGO v2.3.341 with 914 
settings, GO Biological process (23.02.2017) and REACTOME pathways (01.03.2017), 915 
showing only pathways with P-val <= 0.05,  minimum 5 genes per cluster, and default 916 
settings.  917 
In accordance with the NNMF analysis, OPCs and OLs from EAE mice shared an enrichment 918 
for genes involved in the positive regulation of adaptive immune response, positive regulation 919 
of T cell mediated cytotoxicity, response to interferon and antigen processing and 920 
presentation of endogenous peptides via MHC-I (Supplementary Fig. 4b). GO/Reactome 921 
analysis for the enriched genes in individual clusters indicated that OPC2-EAE was enriched 922 
in positive regulation of T cell mediated cytotoxicity, antigen presentation, among other 923 
processes (Supplementary Fig. 5). MOL1/2-EAE exhibited enrichment in similar processes, 924 
but also additional processes related with glycosylation (Supplementary Fig. 5), which has 925 
been implicated in the activation of adaptive immune activation42. In contrast to these 926 
populations, “young” (Pdgfra-H2B-GFP) MOL5/6-EAE-a exhibited less pronounced 927 
upregulation in immune related GO-terms (Supplementary Fig. 5). Instead, this Plin4+ MOL 928 
cluster is enriched in genes related to lipid modification, gliogenesis, and intrinsic apoptotic 929 
signaling pathway (with anti-apoptotic genes Bcl2l1, Cdkn1a and pro-apoptotic genes Bnip3, 930 
Ppp1r13b; Supplementary Table 1), among other categories (Supplementary Fig. 5).  931 
 932 
 933 
Alternative splicing analysis. Alternatively spliced cassette exons were identified with BRIE 934 
0.1.343 in the cell types clusters from Smart-seq2 data. Cassette exons annotations were 935 
extracted from Gencode.vM12 from protein-coding genes according to the parameters in 43. 936 
For each of the cells classified as MOL1/2, MOL5/6 and OPC, the fraction of exon inclusion 937 
 
28
was calculated (PSI), with default parameters. Then, for each cell type, cell to cell pair-wise 938 
comparisons were performed, comparing EAE-assigned with control-assigned cells. 939 
Significantly alternative spliced candidates were selected with the following parameters, 940 
Bayes factor > 10, delta PSI between the two cells > 0.2 and a minimum number of 941 
significant comparisons for each cell type (MOL12 >= 20, OPC >= 20 and MOL56 >= 100). 942 
In order to get more specific alternatively spliced exons, the candidate events were selected 943 
only when they were uniquely spliced in one direction for each cell type, for instance events 944 
that are only skipped in EAE and events only included in EAE. Violin plots of selected events 945 
were plotted using all the PSI values for that specific alternative exon in EAE and in control, 946 
Wilcoxon rank sum test with continuity correction was used for significance test. 947 
Visualization of the alternative spliced events junctions reads was done with the merged bam 948 
files and the sashimi plot option in IGV44. 949 
 950 
MS susceptibility genes. Genes assigned to human MS susceptibility SNPs were transform to 951 
Mus musculus annotation using BioMart 45. Human chrX associated SNPs from ref 2 were 952 
assigned to hg19 GENCODEv19 gene annotations with Bedtools v2.25.046, with parameters 953 
windowbed -60000. Recovered genes were transform to Mus musculus gene symbols using 954 
BioMart. 955 
 956 
Ethics approval and consent to participate. The collection of all animal samples was 957 
performed according to the guidelines and recommendations of local animal protection 958 
legislation and were approved by the local committee for ethical experiments on laboratory 959 
animals in Sweden (Stockholms Norra Djurförsöksetiska nämnd). Human post mortem MS 960 
tissue was provided via a UK prospective donor scheme with full ethical approval from the 961 
UK Multiple Sclerosis Tissue Bank (MREC/02/02/39). All participants gave prospective pre-962 
mortem written consent for their brains to be banked and used for research. 963 
 964 
Code availability. Code used for single cell RNA-Seq analysis is available at 965 
https://github.com/Castelo-Branco-lab/GeneFocus. 966 
 967 
Data availability: A web resource for browsing differential gene expression data for the 968 
single cell data can be accessed at https://ki.se/en/mbb/oligointernode. Raw data is deposited 969 
in GEO, accession number GSE113973. Code used for single cell RNA-Seq analysis is 970 
available at https://github.com/Castelo-Branco-lab/GeneFocus. 971 
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 972 
Supplementary Table information 973 
Supplementary Table S1 – Differential gene expression and gene module associated with clusters 974 
(level 1 and level 2 - oligodendrocytes) identified by single cell RNA-Seq in CFA and EAE mice. n=4 975 
biologically independent mouse spinal cord samples per condition. 976 
Supplementary Table S2 - Splicing events and exon inclusion or exclusion events summarized by 977 
cluster, in single cell RNA-Seq in CFA and EAE mice. n=4 biologically independent mouse spinal 978 
cord samples per condition. 979 
 980 
Supplementary Table S3 - Differential genes expression between CTRL and EAE in MOLs and 981 
OPCs and Gene Ontology terms for comparisons, enriched genes for each cluster, and alternatively 982 
spliced genes between CTRL and EAE. n=4 biologically independent mouse spinal cord samples per 983 
condition. All GO analysis where performed in cytoscape and p <0.05; p values were calculated with 984 
Bonferroni two-sided hipergeometric test. 985 
 986 
Supplementary Table S4 - Non-MHC MS susceptibility genes expressed in microglia and OPCs in 987 
EAE and CTRL and significant differential expression across the major level 1 clusters. 988 
 989 
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